In prostate cancer cell line models <i>CHD1</i> deletion did not induce HR deficiency as detected by RAD51 foci formation assay or mutational signatures, which was consistent with the moderate increase of olaparib sensitivity. The gene discussed is CHD1; the disease is prostate cancer.